カタルーニャの公衆衛生システムにおける精密腫瘍学プログラムの実施:結果,教訓,将来展望
Pilar Mur1,2, Anna Pozuelo3, Josep Tabernero4,5
1Catalonian Cancer Strategy, Department of Health, Biomedical Research Institute of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. pmur@catsalut.cat.
まとめ
カタロニアの精密腫瘍学プログラム (POP) は,公正ながん検査のために次世代配列解析 (NGS) を成功裏に統合しました. これは24.7%の患者の個別化された治療につながり,がん治療を改善しました.
科学分野:
- 腫瘍学
- ゲノミクス
- 公衆衛生
背景:
- カタルーニャの精密腫瘍学プログラム (POP) は,がん患者の高度な分子検査への公平なアクセスを確保するために設立されました.
- 次世代シーケンシング (NGS) の統合は,成人および小児の悪性腫瘍の診断,予後および治療決定を導くことを目的としています.
研究 の 目的:
- カタルーニャの精密腫瘍学プログラム (POP) の成果と影響を評価する.
- がん治療のルーティン臨床実践に NGS の統合を評価する.
主な方法:
- この研究では,2022年から2023年に焦点を当てて,2021年7月から2023年12月のデータを評価した.
- CatSalutによって調整された12の基準センターから,試験量,パネルタイプ,および臨床結果を含むデータが収集されました.
主要な成果:
- 22501人の患者に23,000以上の分子検査が行われ,生殖線変異 (42. 2%) と固形腫瘍 (38. 1%) が最も一般的であった.
- 患者の24. 7%の臨床管理が変化し,特に固体腫瘍 (58. 7%) で,よりターゲットを絞った治療が可能になった.
- 平均的な報告の処理時間は4週間で,サンプル提出の適合率は98.5%でした.
結論:
- POPは実施の課題を効果的に克服し,分子試験への公平なアクセスを確保しました.
- このプログラムは個別化されたがん管理を容易にし 患者の治療結果とケア効率に ポジティブな影響を及ぼしました
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Prevention
6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.3K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K


